Biomind Labs Inc. (BMNDF)
USD 0.7
(150.27%)
USD 0.7
(150.27%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 73.81 Thousand USD | -17.12% |
| 2022 | 89.06 Thousand USD | -96.48% |
| 2021 | 2.52 Million USD | 2782.71% |
| 2020 | 87.69 Thousand USD | -76.34% |
| 2019 | 370.66 Thousand USD | -76.42% |
| 2018 | 1.57 Million USD | -90.92% |
| 2017 | 17.31 Million USD | 0.57% |
| 2016 | 17.21 Million USD | -0.22% |
| 2015 | 17.25 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 73.21 Thousand USD | -0.82% |
| 2024 Q2 | 57.74 Thousand USD | -21.14% |
| 2023 Q1 | 77.51 Thousand USD | -12.97% |
| 2023 Q3 | 157.99 Thousand USD | 43.99% |
| 2023 FY | 73.81 Thousand USD | -17.12% |
| 2023 Q2 | 109.72 Thousand USD | 41.56% |
| 2023 Q4 | 73.81 Thousand USD | -53.28% |
| 2022 Q2 | 1.17 Million USD | -35.09% |
| 2022 FY | 89.06 Thousand USD | -96.48% |
| 2022 Q4 | 89.06 Thousand USD | -82.82% |
| 2022 Q1 | 1.8 Million USD | -28.48% |
| 2022 Q3 | 518.37 Thousand USD | -55.83% |
| 2021 Q2 | 98.28 Thousand USD | 83.02% |
| 2021 FY | 2.52 Million USD | 2782.71% |
| 2021 Q1 | 53.7 Thousand USD | 0.0% |
| 2021 Q4 | 2.52 Million USD | -21.53% |
| 2021 Q3 | 3.22 Million USD | 3177.98% |
| 2020 FY | 87.69 Thousand USD | -76.34% |
| 2019 FY | 370.66 Thousand USD | -76.42% |
| 2018 FY | 1.57 Million USD | -90.92% |
| 2017 FY | 17.31 Million USD | 0.57% |
| 2016 FY | 17.21 Million USD | -0.22% |
| 2015 FY | 17.25 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -3095.628% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 96.23% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.301% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 86.63% |
| Rebus Holdings, Inc. | 5000.00 USD | -1376.38% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.943% |
| Qrons Inc. | 420.00 USD | -17475.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 90.421% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.736% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 84.639% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.382% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.81% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.978% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 3.32% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.931% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 94.845% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2.009% |
| Mesoblast Limited | 667.9 Million USD | 99.989% |
| Marizyme, Inc. | 22.01 Million USD | 99.665% |
| Genus plc | 1.02 Billion USD | 99.993% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 94.566% |
| Pharming Group N.V. | 462.85 Million USD | 99.984% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 97.772% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 85.208% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 88.227% |
| ContraFect Corporation | 20.67 Million USD | 99.643% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 81.09% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 80.685% |
| IMV Inc. | 31.33 Million USD | 99.764% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 98.22% |
| MultiCell Technologies, Inc. | 126.22 USD | -58384.392% |
| ONE Bio Corp. | 70.08 Million USD | 99.895% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 92.144% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.943% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 82.901% |
| Q BioMed Inc. | 3.51 Million USD | 97.9% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.79% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 71.747% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.983% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 94.905% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.754% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 97.312% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 89.262% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 97.164% |
| GB Sciences, Inc. | 103.44 Thousand USD | 28.637% |
| Alpha Cognition Inc. | 2.45 Million USD | 96.99% |
| HST Global, Inc. | 1526.00 USD | -4737.418% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 92.528% |
| Halberd Corporation | 10.13 Thousand USD | -628.645% |
| Enzolytics Inc. | 361.7 Million USD | 99.98% |
| Agentix Corp. | 261.39 Thousand USD | 71.759% |
| Resverlogix Corp. | 8.11 Million USD | 99.09% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 96.069% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.845% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 88.46% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -224.038% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.175% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.999% |
| Zenith Capital Corp. | 7410.00 USD | -896.208% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 184.00 USD | -40019.022% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 77.061% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 71.756% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 92.045% |
| Kadimastem Ltd | 2.3 Million USD | 96.796% |
| Helix BioMedix, Inc. | 3.02 Million USD | 97.56% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.86% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.493% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -29.294% |
| LadRx Corporation | 2.3 Million USD | 96.801% |
| Cell Source, Inc. | 195.17 Thousand USD | 62.177% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 79.125% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 79.125% |
| NovAccess Global Inc. | 62.24 Thousand USD | -18.589% |
| Affymax, Inc. | 7.44 Million USD | 99.008% |
| Itoco Inc. | 1.4 Million USD | 94.727% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 22.829% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 30.359% |
| Mobile Lads Corp. | 52.00 USD | -141859.615% |
| CytoDyn Inc. | 11.13 Million USD | 99.337% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 48.368% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -312.858% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 80.85% |
| SYBLEU INC | 330.46 Thousand USD | 77.662% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 81.97% |
| International Stem Cell Corporation | 5.39 Million USD | 98.63% |
| Bioxytran, Inc. | 137.63 Thousand USD | 46.367% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.508% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.555% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 6.558% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 91.463% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.018% |
| Neutra Corp. | 2851.00 USD | -2489.232% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.772% |
| PureTech Health plc | 693.97 Million USD | 99.989% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.085% |
| IXICO plc | 15.84 Million USD | 99.534% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.109% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.929% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.978% |